Category Archives: Immunology

AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology…

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--AgilVax Inc., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics, announced today that preclinical data describing M5, the Companys monoclonal antibody targeting xCT, will be presented by Dr. Salameh at the American Association for Cancer Researchs Tumor Immunology and Immunotherapy Conference being held at the Boston Marriott Copley Place in Boston, MA.

Title:

Development of a monoclonal antibody targeting xCT/SLC7A11 expressed in metastatic cancer cells

Poster Session:

Poster Session B

Session Date:

Tuesday, November 19

Board Number (poster number):

B37

Time:

4:30 p.m. to 7:00 p.m.

Session Location:

Back Bay

We are pleased with our continued progress on developing multiple solutions to target cancer cells overexpressing xCT and thrilled to have the opportunity to showcase our advancements in a poster presentation at such a prestigious meeting, said Dr. Joseph Patti, President and CEO of AgilVax. Dr. Patti further stated, xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVaxs antibody-based therapeutics have shown reduction of primary tumor formation and lung metastases illustrating the potential to create durable responses in patients suffering from colorectal and other metastatic cancers.

About AgilVax

AgilVax is a biopharmaceutical company that discover and develops targeted antibody-based products to treat multiple types of cancer. The Company has three development programs; an unmodified monoclonal antibody (mAb) targeting xCT, an antibody-drug conjugate targeting xCT, and AX09, a VLP-based xCT vaccine currently in cGMP production.

For more information, please visit http://www.agilvax.com

Originally posted here:
AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research's Tumor Immunology...

Immunology Market 2019 production, revenue, price, market share and growth rate upto 2025 – Press X Now

The Immunology market report offers an in-depth analysis of the on-going trends, Immunology Market drivers, different opportunities and high-growth areas which would help clients to articulate Immunology market strategies according to the current and future industry trends. The Immunology market study also covers the regional and global analysis of this industry. Furthermore, it examines and meanwhile, represents the worldwide Immunology market size of the significant players in each region around the different corner of the world.

Request a sample copy of this report at: https://marketresearchexpertz.com/report/global-immunology-market-28675#request-sample

Reportedly, the global Immunology market report accounted for xx billion in 2018 and it is projected to gather xx billion US$ by 2026, along with a growing CAGR of xx % during the forecast timeframe. Several factors including increasing demand for upgrading of the Immunology market, rising demand of the industry from developing economies, and expanding the use of Immunology market over distinct sectors are propelling the universal market.

Key Manufacturers functioning in this market are:AbbVieAmgenF. Hoffmann-La RocheJohnson & JohnsonBionor PharmaCelgeneCellectar BioscienceseFFECTOR Therapeutics

Global Immunology market segregation by type:Immuno BoostersImmunosuppressants

The Application of Immunology market can be split into:Autoimmune DiseasesOncologyOrgan TransplantationOthers

The elaborated study delivers a brief appraisal of the Immunology market that helps stakeholders to gain a solid base in this industry. The main motive of the Global Immunology market 2019 report is to offer industry investors, customers, and company officials with important statistics to assist them to create reliable industrial decisions related to the essential opportunities in the Immunology market.

This research study also pinpoints business insights and offers an analysis of the extremely significant trends that are anticipated to affect the Immunology market outlook from the year 2019 to 2026. The report also incorporates the production capacity, value chain structure, raw material sources as well as suppliers, import/export, product portfolios, and technology adoptions. Their financial status is also analyzed in the worldwide Immunology market report which studies pricing structure, growth rate, gross margin, fiscal ratios, product value, cash flow, sales volume and much more. The evaluation of the Immunology market also promotes clients to grab a clear understanding of the Immunology industry position at global level, strengths and weakness of their rivals too.

Browse More Details: https://marketresearchexpertz.com/report/global-immunology-market-28675

The research report on the Global Immunology market will surely help major market players as well as new entrants to understand the international industry in detail. Moreover, this study also encourages industry vendors to decide their business strategies and work hard to achieve their proposed business aims.

Read the original post:
Immunology Market 2019 production, revenue, price, market share and growth rate upto 2025 - Press X Now

Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day – Yahoo Finance

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Guggenheim Healthcare Talks Neuro/Immunology Day on Monday, November 18 at 1:00 p.m. ET.

A live webcast of the presentation will be available on the Events and Presentations page in the Investors section of the companys website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the companys website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005228/en/

Go here to read the rest:
Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day - Yahoo Finance

CSU lands $1.2 million in NIH funding to advance work on a new tuberculosis vaccine – Source

At CSU, the research will include a multidisciplinary team of at least 20 researchers, students and staff, including Assistant Professors Michael Lyons and Brooke Anderson, Research Scientists Carolina Mehaffy and Andres Obregon Henao, Associate Professor Diane Ordway, and Corey Broeckling, director of the Proteomics and Metabolomics Facility.

Henao-Tamayo, whose TB research has been focused on vaccines, said the project aims to combine expertise from all over the world. It will include experiments to better understand previous research she conducted in collaboration with the late Ian Orme, a CSU University Distinguished Professor, to study environmental mycobacteria, which live in water and soil, and how these organisms may interfere immunologically with the protection that the BCG vaccine provides against TB.

Podell, who earned doctorates in veterinary medicine and pathology from CSU, said the initiative will be perhaps the most comprehensive pathology assessment of vaccine and TB immunity ever done.

Podell and Henao-Tamayo said that the award reflects not only the outstanding reputation of CSUs Mycobacteria Research labs, but also provides a boost of recognition for the program.

Brendan and I were both trained in these labs, and were now leading the charge on this new research, said Henao-Tamayo.

Additional partners include Oxford University; Public Health England; Statistical Center for HIV/AIDS Research and Prevention at Fred Hutchinson Cancer Research Center; Ragon Institute of MGH, MIT and Harvard; Denver Veterans Affairs Medical Center; National Jewish Health in Denver, and La Jolla Institute for Immunology.

NIAID recently awarded contracts totaling $30 million for the first year to provide up to seven years of support for three Immune Mechanisms of Protection Against Mycobacterium tuberculosis (IMPAc-TB) Centers. The Centers aim to better explain the immune responses required for protection from TB-causing Mycobacterium tuberculosis bacteria. Harvard T.H. Chan School of Public Health and Seattle Childrens Hospital will lead research for the other two centers.

Excerpt from:
CSU lands $1.2 million in NIH funding to advance work on a new tuberculosis vaccine - Source

Anaphylaxis patients forced to wait more than a year for testing – The Canberra Times

news, latest-news, allergies, allergy, anaphylaxis, food allergies, allergy inquiry, immunology

Those living with life-threatening allergies are being forced to wait up to more than a year just to receive treatment, with experts saying wait times are set to get even worse. As the number of adults being diagnosed with anaphylaxis increases, immunologists and allergy specialists are reporting they are often unable to keep up with demand for testing and treatment. Allergy and Anaphylaxis Australia chief executive Maria Said said allergy sufferers seeking a diagnosis and specialist testing from immunologists are being put at risk due to the increased wait times. "When you have a life-threatening reaction, it could be between 12 and 18 months before an appointment, and that's really unacceptable considering the impact that allergic diseases have on people's quality of life," Ms Said said. "This has the potential to be a lot worse." A study from the Australian Society of Clinical Immunology and Allergy found 10 per cent of infants, up to 8 per cent of children and 2 per cent of adults reported having some form of food-related allergy. A National Health Survey from 2015 also found 3.1 per cent of Australians reported an "undefined allergy", with other forms of anaphylaxis including exposure to mould, insect bites or latex. Ms Said said increased wait times were being seen across Australia, with even longer wait times out of the major capital cities. A spokeswoman for Canberra Health Services said data on average wait times to see ACT-based immunologists was not collected. "Immunologists also deal with patients with other conditions, including serious autoimmune and inflammatory diseases and immune deficiencies," the spokeswoman said. "As a result, there is considerable demand for appointments. There are six immunologists employed by Canberra Health Services, all with part-time appointments." Canberra immunologist Dr Raymond Mullins said while wait times vary from state to state, public hospital outpatient waiting lists are normally more than 12 months. "Food allergies and anaphylaxis have moved from a marginal phenomena to an ongoing public health issue for an increasing proportion of the population and their caregivers," Dr Mullins said. "This has implications in terms of cost of care, the need for medical visits and review, the use and availability of emergency medication such as EpiPens." While data from the ACT is not available, figures from Victoria showed a median waiting time of more than 100 days to access immunologists for allergy testing. Dr Mullins said more people were in need of seeing immunologists as children who developed allergies got older. "Young children who have nut allergies will generally still have persistent food allergy 80 per cent time," he said. "That means we have an ageing population of teenagers and young adults with persistent food allergy at greater risk of having more serious reactions including fatalities." Ms Said said as more adults were experiencing severe allergies, many immunology clinics have been unable to keep up with demand, with many clinics only specialising in paediatrics. "There's only a handful of public clinics, and most are specifically for children, yet there's a growing number of adults with allergic diseases," she said. "It's very concerning because allergic diseases can't be cured and it has to be managed, and people need to be educated on how it can be managed." READ MORE: The access to treatment for those with anaphylaxis forms part of a federal government inquiry into severe allergies. In its submission to the inquiry, the federal Health Department said Australia had one of the highest rates of allergies and anaphylaxis in the world. "Available evidence from hospital admissions for anaphylaxis indicates the prevalence has increased in many western countries, including Australia," the department said. "Total hospital admissions rates for all causes of anaphylaxis increased by 8 per cent each year between 1997 and 2013." The Australian Society of Clinical Immunology and Allergy has told the inquiry the current access process for immunology testing was time-consuming and complicated, calling for access to be simplified. Ms Said said more public clinics were needed in order to reduce wait times for those with anaphylaxis. "We need them especially in rural and remote areas to allow for greater access to an accurate diagnosis and accurate information on allergy management," she said.

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/fdcx/doc715sqbsljww17409n8yp.jpg/r17_381_3989_2625_w1200_h678_fmax.jpg

SUBSCRIBER

November 18 2019 - 4:30AM

Those living with life-threatening allergies are being forced to wait up to more than a year just to receive treatment, with experts saying wait times are set to get even worse.

As the number of adults being diagnosed with anaphylaxis increases, immunologists and allergy specialists are reporting they are often unable to keep up with demand for testing and treatment.

Allergy and anaphylaxis patients are being forced to wait months to see public immunologists and specialists. Picture: Elesa Kurtz

Allergy and Anaphylaxis Australia chief executive Maria Said said allergy sufferers seeking a diagnosis and specialist testing from immunologists are being put at risk due to the increased wait times.

"When you have a life-threatening reaction, it could be between 12 and 18 months before an appointment, and that's really unacceptable considering the impact that allergic diseases have on people's quality of life," Ms Said said.

"This has the potential to be a lot worse."

A study from the Australian Society of Clinical Immunology and Allergy found 10 per cent of infants, up to 8 per cent of children and 2 per cent of adults reported having some form of food-related allergy.

A National Health Survey from 2015 also found 3.1 per cent of Australians reported an "undefined allergy", with other forms of anaphylaxis including exposure to mould, insect bites or latex.

Ms Said said increased wait times were being seen across Australia, with even longer wait times out of the major capital cities.

Food allergies have shifted from being a fringe issue to a major public health concern. Picture: Shutterstock

A spokeswoman for Canberra Health Services said data on average wait times to see ACT-based immunologists was not collected.

"Immunologists also deal with patients with other conditions, including serious autoimmune and inflammatory diseases and immune deficiencies," the spokeswoman said.

"As a result, there is considerable demand for appointments. There are six immunologists employed by Canberra Health Services, all with part-time appointments."

Canberra immunologist Dr Raymond Mullins said while wait times vary from state to state, public hospital outpatient waiting lists are normally more than 12 months.

"Food allergies and anaphylaxis have moved from a marginal phenomena to an ongoing public health issue for an increasing proportion of the population and their caregivers," Dr Mullins said.

"This has implications in terms of cost of care, the need for medical visits and review, the use and availability of emergency medication such as EpiPens."

The availability of EpiPens is now a core health concern for public institutions. Picture: Shutterstock

While data from the ACT is not available, figures from Victoria showed a median waiting time of more than 100 days to access immunologists for allergy testing.

Dr Mullins said more people were in need of seeing immunologists as children who developed allergies got older.

"Young children who have nut allergies will generally still have persistent food allergy 80 per cent time," he said.

"That means we have an ageing population of teenagers and young adults with persistent food allergy at greater risk of having more serious reactions including fatalities."

Ms Said said as more adults were experiencing severe allergies, many immunology clinics have been unable to keep up with demand, with many clinics only specialising in paediatrics.

"There's only a handful of public clinics, and most are specifically for children, yet there's a growing number of adults with allergic diseases," she said.

"It's very concerning because allergic diseases can't be cured and it has to be managed, and people need to be educated on how it can be managed."

The access to treatment for those with anaphylaxis forms part of a federal government inquiry into severe allergies.

In its submission to the inquiry, the federal Health Department said Australia had one of the highest rates of allergies and anaphylaxis in the world.

"Available evidence from hospital admissions for anaphylaxis indicates the prevalence has increased in many western countries, including Australia," the department said.

"Total hospital admissions rates for all causes of anaphylaxis increased by 8 per cent each year between 1997 and 2013."

The Australian Society of Clinical Immunology and Allergy has told the inquiry the current access process for immunology testing was time-consuming and complicated, calling for access to be simplified.

Ms Said said more public clinics were needed in order to reduce wait times for those with anaphylaxis.

"We need them especially in rural and remote areas to allow for greater access to an accurate diagnosis and accurate information on allergy management," she said.

Here is the original post:
Anaphylaxis patients forced to wait more than a year for testing - The Canberra Times

PhD Program | Immunology | Stanford Medicine

The Immunology doctoral program offers instruction and research opportunities leading to a Ph.D. in Immunology. Two tracks are offered:

The goal of the Ph.D. Program in Immunologyis to develop investigators who have a strong foundation in Immunology and related sciences in order to carry out innovative research. The program features a flexible choice of courses and seminars combined with extensive research training in the laboratories of participating Immunology faculty. Specifically, immunology graduate students:

Read more:
PhD Program | Immunology | Stanford Medicine

Current Research in Immunology – Journal – Elsevier

Current Research in Immunology (CRIMMU) is a new primary research journal, gold open access journal from Elsevier. CRIMMU publishes original papers and short communications that cover all aspects of molecular and cellular immunology.

Current Research in Immunology is a peer-reviewed gold open access...

Current Research in Immunology (CRIMMU) is a new primary research journal, gold open access journal from Elsevier. CRIMMU publishes original papers and short communications that cover all aspects of molecular and cellular immunology.

Current Research in Immunology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Immunology (2018 CiteScore 7.080) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.

Current Research in Immunology topics covered include (but are not restricted to):

Topics which may be considered for the journal only if the following requirements are met:

Current Research in Immunology builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. For more information, please refer to: http://www.elsevier.com/conflictsofinterest

Visit link:
Current Research in Immunology - Journal - Elsevier

Department of Immunology

UW holds No. 4 position on global rankings among US universities

The University of Washington again placed fourth among U.S. higher education institutions, according to the NTU Rankings. For the first time, UW Immunology placed fourth in the world among the subjects at the UW that ranked in the top ten worldwide. The NTU ranking is entirely based on scientific papers, reflecting scientific performance from three perspectives on research productivity, impact and excellence read more

The Department of Immunology is a basic science department within the University of Washington, School of Medicine located in Seattle.

Our mission is to advance understanding of the function of the immune system in order to enhance our ability to fight infectious disease, cancer and autoimmune disease. Basic research of all aspects of immunology is critical to this mission, as well as translational research to link our findings to the development of new therapies.

We hold diversity and inclusiveness as core values in our department and emphasize their importance throughout our research, education and practice. We strive to create a climate that fosters belonging, respect and value for all within our scientific community and the institution.

Make a Gift

Read more:
Department of Immunology

Home – IMMUNOLOGY 2020

Six single-column sponsorships are available directly outside of the scientific sessions, and four double-column sponsorships are available in the area of Registration and the Exhibit Hall Entrance. Each sponsorship includes full wrap of the column(s) with your branding and artwork.

Qualifies for Premier Sponsorship Level if over $3,000

Read more:
Home - IMMUNOLOGY 2020